Oncology and Therapy

Palbociclib in HR-positive, HER2-negative advanced/metastatic breast cancer: A systematic scoping review of real-world evidence from countries outside of Western regions that are underrepresented in clinical trials

Reviews in Cardiovascular Medicine

Risk of cardiovascular events with cyclin-dependent kinases 4 and 6 (CDK 4/6) inhibitors among patients with advanced breast cancer: A systematic review and network meta-analysis

Radiology Case Reports

Palbociclib and fulvestrant combined regimen induced prolonged bone metastasis control of stage IV HR+/HER2- breast cancer: A case report

Anticancer Research

Risk factors for non-sentinel lymph node metastasis in HR+/HER2- breast cancer with cN0

npj Breast Cancer

Impact of dose reductions on adjuvant abemaciclib efficacy for patients with high-risk early breast cancer: analyses from the monarchE study

Current Opinion in Oncology

Controversies on chemotherapy for early HR+/HER2- breast cancer: The role of anthracyclines and dose intensification

Cancers (Basel)

Social determinants of health and other predictors in initiation of treatment with CDK4/6 inhibitors for HR+/HER2- metastatic breast cancer

Journal of Clinical Medicine

Novel treatment strategies for hormone receptor (HR)-positive, HER2-negative metastatic breast cancer